# Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

> **NCT05174650** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 27 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Derazantinib

## Key facts

- **NCT ID:** NCT05174650
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-20
- **Primary completion:** 2025-12
- **Final completion:** 2026-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174650, "Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05174650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*